Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Sarepta Therapeutics, Inc. (SRPT : NSDQ)
 
 • Company Description   
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease.

Number of Employees: 1,372

 
 • Price / Volume Information   
Yesterday's Closing Price: $18.67 Daily Weekly Monthly
20 Day Moving Average: 6,015,894 shares
Shares Outstanding: 97.71 (millions)
Market Capitalization: $1,824.31 (millions)
Beta: 0.52
52 Week High: $138.81
52 Week Low: $10.42
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -20.15% -20.65%
12 Week -8.48% -12.92%
Year To Date -84.64% -86.71%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
215 FIRST STREET SUITE 415
-
CAMBRIDGE,MA 02142
USA		 ph: 617-274-4000
fax: 425-354-5038		 investors@sarepta.com http://www.sarepta.com
 
 • General Corporate Information   
Officers
Douglas S. Ingram - President; Chief Executive Officer
M. Kathleen Behrens - Chairwoman of the Board
Ian M. Estepan - Executive Vice President; Chief Financial Officer
Richard Barry - Director
Deirdre Connelly - Director

Peer Information
Sarepta Therapeutics, Inc. (CORR.)
Sarepta Therapeutics, Inc. (RSPI)
Sarepta Therapeutics, Inc. (CGXP)
Sarepta Therapeutics, Inc. (BGEN)
Sarepta Therapeutics, Inc. (GTBP)
Sarepta Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 803607100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/25/26
Share - Related Items
Shares Outstanding: 97.71
Most Recent Split Date: 7.00 (0.17:1)
Beta: 0.52
Market Capitalization: $1,824.31 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.06 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.30 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 18.30% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/25/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.38
Price/Cash Flow: 7.66
Price / Sales: 0.76
EPS Growth
vs. Year Ago Period: -216.67%
vs. Previous Quarter: -116.47%
Sales Growth
vs. Year Ago Period: -14.52%
vs. Previous Quarter: -34.65%
ROE
09/30/25 - -4.85
06/30/25 - -1.03
03/31/25 - -14.88
ROA
09/30/25 - -1.78
06/30/25 - -0.37
03/31/25 - -5.12
Current Ratio
09/30/25 - 2.95
06/30/25 - 2.89
03/31/25 - 4.02
Quick Ratio
09/30/25 - -
06/30/25 - 1.81
03/31/25 - 2.46
Operating Margin
09/30/25 - -2.69
06/30/25 - -0.54
03/31/25 - -8.28
Net Margin
09/30/25 - -11.25
06/30/25 - -2.34
03/31/25 - -11.12
Pre-Tax Margin
09/30/25 - -10.45
06/30/25 - -0.97
03/31/25 - -7.35
Book Value
09/30/25 - 13.51
06/30/25 - 13.81
03/31/25 - 11.63
Inventory Turnover
09/30/25 - 0.61
06/30/25 - 0.63
03/31/25 - 0.59
Debt-to-Equity
09/30/25 - 0.78
06/30/25 - 0.84
03/31/25 - 1.00
Debt-to-Capital
09/30/25 - 43.95
06/30/25 - 45.64
03/31/25 - 49.90
 

Powered by Zacks Investment Research ©